HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jeremy Yates Selected Research

Cetuximab (Erbitux)

3/2013Early postoperative epidermal growth factor receptor inhibition: safety and effectiveness in inhibiting microscopic residual of oral squamous cell carcinoma in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jeremy Yates Research Topics

Disease

1Squamous Cell Carcinoma of Head and Neck
03/2013
1Residual Neoplasm
03/2013
1Lymphatic Metastasis
03/2013
1Neoplasms (Cancer)
03/2013
1Infections
05/2009

Drug/Important Bio-Agent (IBA)

1ErbB Receptors (EGF Receptor)IBA
03/2013
1Cetuximab (Erbitux)FDA Link
03/2013
1LigandsIBA
03/2013
1Viral ProteinsIBA
05/2009

Therapy/Procedure

1Therapeutics
03/2013